Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinonasal Therapies De-escalation in CF Patients on HEMT
NCT06996951Phase 3Recruiting
- Sponsor
- Indiana University
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cystic fibrosis (CF) and chronic rhinosinusitis (CRS) (2 arms), sponsored by Indiana University. Primary endpoints: Lund Kennedy Score at 12 weeks, Pulmonary Function Testing at 12 weeks and 5 more. Started Jul 2025; status: recruiting.
02
Conditions
cystic fibrosis (CF)chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT06996951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996951.